<p>This study sheds light on the promising potential of chitosan-coated mesoporous silica nanoparticles (MSN) as an innovative drug delivery system, specifically aimed at fostering the growth and repair of enthesis organs. MSN, meticulously engineered and loaded with potent therapeutic agents, such as dexamethasone and transforming growth factor beta (TGF- β), have demonstrated controlled and sustained release of these agents. This is a critical feature given the extended healing processes typically associated with enthesis repair. The experimental results obtained from this study, including comprehensive physicochemical characterizations and in vitro assays, validate the effectiveness of this approach. Moreover, the biocompatibility of the chitosan coating enhances its therapeutic potential by creating a microenvironment conducive to tissue regeneration, thereby enhancing the overall efficacy of the treatment. Sustained drug release and enhanced signaling facilitated by MSN potentially lead to more effective and long-lasting healing. In summary, the utilization of surface-modified mesoporous silica nanoparticles (MSN) for prolonged drug delivery is a promising technique for enhancing the treatment of enthesis injuries. This method could enhance the efficacy and longevity of medications, offering substantial advantages to patients in the medical field.</p>